Heart Test Labs obtains temporary stay of Nasdaq delisting; hearing set for June 27

HeartSciences Inc.

Nasdaq delisting action stayed pending oral hearing on June 27, 2024.
Company implemented 1-for-100 reverse stock split on May 17, 2024.
Previously, stock closed at $0.10 or less for 10 consecutive days triggering Low Priced Stocks Rule.
Company intends to argue it has regained compliance with Minimum Bid Price and Low Priced Stocks Rules.
No assurance of successful appeal; shares continue trading under HSCS and HSCSW pending outcome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.